Transmission of human T cell leukemia virus type I to sheep: antibody profile and detection of viral DNA sequences.
Lambs were inoculated intraperitoneally with either 1.8 x 10(7) live peripheral blood cells from an HTLV-I-infected person (five lambs) or with 8 x 10(7) live cells from the HTLV-I-producing cell lines MT-2 (four lambs) or C10 MJ (five lambs). Four control lambs were inoculated with minimal essential medium supplemented with fetal calf serum. The animals were monitored during a period of 24 months. Beginning at 5 to 12 months after inoculation, four of the five lambs inoculated with the fresh HTLV-I-infected peripheral blood cells began to develop detectable levels of antibodies to a recombinant HTLV-I gp21env antigen, as determined by an enzyme-linked immunoassay (ELISA). The anti-gp21 antibodies persisted for the remaining observation period. These antibodies were not detected in the sera from the other sheep. Absorption and blocking experiments demonstrated the specificity of the gp21 reactivity. This reactivity was also confirmed by Western blot (WB). With the exception of the serum of an MT-2-inoculated sheep that formed a weak band with p19 by WB, none of the sera of the four gp21-positive sheep or of the other experimental sheep reacted with other structural or regulatory HTLV-I proteins, as determined by ELISA, WB, and radioimmunoassay. PCR analyses demonstrated the presence of the HTLV-I provirus in peripheral blood leukocytes of the four sheep showing antibodies to gp21env. The remaining sheep were negative. PCR analyses failed to detect BLV sequences in any of the experimental sheep. None of the sheep showed clinical abnormalities during the observation period. The potential value of the sheep model for studying atypical virus-host interactions in infected people is discussed.
Esteban
E N
EN
New Bolton Center, University of Pennsylvania 19348, USA.
Sherman
M P
MP
Poiesz
B L
BL
Marshak
R R
RR
Waters
D J
DJ
Ferrer
J F
JF
D000818:Animals; D002461:Cell Line, Transformed; D004279:DNA, Viral / Q000097:blood*; D015686:Gene Products, env / Q000276:immunology; D015481:HTLV-I Antibodies / Q000097:blood*; D015486:HTLV-I Antigens / Q000276:immunology; D015490:HTLV-I Infections / Q000097:blood / Q000276:immunology / Q000821:virology*; D015368:Human T-lymphotropic virus 1 / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins / Q000276:immunology; D015682:Retroviridae Proteins, Oncogenic / Q000276:immunology; D012756:Sheep; D014407:Tumor Cells, Cultured; D054299:env Gene Products, Human Immunodeficiency Virus
D004279:DNA, Viral; D015686:Gene Products, env; D015481:HTLV-I Antibodies; D015486:HTLV-I Antigens; D011994:Recombinant Proteins; D015682:Retroviridae Proteins, Oncogenic; D054299:env Gene Products, Human Immunodeficiency Virus; C055265:gp21 protein, Human T-lymphotropic virus 1; C060954:p24 protein, Human T-lymphotropic virus 1